Ignite Creation Date:
2024-05-06 @ 4:09 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04891900
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2021-05-05
Brief Title:
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
A Single Arm Multicenter Phase II Clinical Study of TQB2450 PD-L1 Inhibitor Plus Anlotinib Combined With Oxaliplatin Capecitabine in the First-line Treatment of Advanced Gastric Cancer GC or Adenocarcinoma of Esophagogastric Junction AEG
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
Not yet recruiting
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 PD-L1 inhibitor anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced recurrent or metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None